Grace Anyango, a 34-year-old mother of two living in Kibera, Nairobi, has taken five different antidepressants in the past two years. She started on fluoxetine in early 2024, but when the Mathare clinic ran out, she was switched to amitriptyline. Months later, that too was unavailable. Then came imipramine, then escitalopram. Today, she reports no sustained relief. Her story is not unusual. Clinicians in Nairobi say regimen cycling — forced medication switches due to stockouts — is common, leaving patients without consistent treatment for a condition that requires continuity.

A Patient in Kibera Cycles Through Five Antidepressants in Two Years

Grace Anyango first sought help at the Mathare Mental Health Clinic in early 2024. She was diagnosed with moderate depression and started on fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is on Kenya's essential medicines list. For three months, she felt improvement. Then the clinic's pharmacy ran out of fluoxetine. The next available drug was amitriptyline, a tricyclic antidepressant with a different side-effect profile. Grace experienced drowsiness and dry mouth, but she continued. In late 2024, amitriptyline stock dried up, and she was given imipramine. By early 2025, that too was gone. Now she takes escitalopram, another SSRI, but she says the relief is inconsistent.

Dr. Peter Kamau, a psychiatrist at Kenyatta National Hospital, says he sees similar cases weekly. "Patients come in with a new prescription, but the pharmacy has only one or two options. We write what's available, not what's ideal." A 2023 survey by the Kenya Mental Health Alliance, titled "Mental Health Medicines Availability in Public Facilities," found that nearly 40% of patients in public clinics had switched antidepressants at least once in the previous year due to stockouts. For Grace, the switches have left her skeptical. "Each time I start a new drug, I hope it works. But after a few months, I have to change again. I don't know if any of them really help."

Grace's experience reflects a broader problem. Kenya's public mental health system serves millions, but antidepressant availability is erratic. The Kenya Medical Supplies Authority (KEMSA) procures medicines in bulk, but distribution to facilities is uneven. Urban clinics like Mathare may receive stock quarterly, but rural facilities often wait longer. When a drug runs out, clinicians substitute from what is on hand. The result is a patchwork of treatments that rarely align with clinical guidelines recommending 6–12 months of uninterrupted therapy.

The cost of this cycling extends beyond symptoms. Patients like Grace lose work days, strain family relationships, and often drop out of care. Community health workers in Kibera report that clinic attendance drops sharply after a second or third medication switch. "Patients feel the system is failing them," says Mary Wanjiku, a community health volunteer. "Some stop coming altogether. They say, 'What's the point? The medicine will change anyway.'"

The Mechanism of Antidepressant Discontinuation and Relapse

Antidepressants work by modulating neurotransmitter levels in the brain, particularly serotonin and norepinephrine. SSRIs like fluoxetine have a long half-life — roughly 4–6 days — which allows a gradual taper if discontinuation is planned. But when a patient is forced to switch abruptly due to stockouts, the body experiences withdrawal-like symptoms. Fluoxetine's long half-life means it exits the system slowly, but tricyclics like amitriptyline have shorter half-lives, creating a mismatch. Patients may experience dizziness, nausea, anxiety, and sleep disturbances — symptoms that mimic depression relapse.

Dr. Kamau explains: "When you stop one antidepressant and start another, the brain's receptors have to adapt. If the new drug is a different class, the adaptation is more disruptive. We see relapse rates of 50–60% within three months of a forced switch." A 2022 study in the Journal of Clinical Psychiatry (Baldwin et al., "Relapse Risk After Abrupt Antidepressant Discontinuation") estimated that abrupt discontinuation of antidepressants leads to relapse in roughly half of patients, compared to 20% among those who complete a full course. The mechanism involves serotonin receptor downregulation; sudden withdrawal leaves receptors hypersensitive, triggering a rebound of depressive symptoms.

For Grace, each switch has been accompanied by two to three weeks of severe anxiety and insomnia. "I thought I was getting worse," she says. "The doctors said it was side effects, but I didn't know if the new medicine was making me sick." The experience is common. A paper in the Lancet Psychiatry (2021) noted that forced medication changes due to supply failures constitute a form of "iatrogenic instability" — treatment-induced harm. The authors called for supply chain reforms to protect patients from such disruptions.

Kenya's supply chain fails to maintain continuous therapy for several reasons. First, procurement cycles are often quarterly, but demand forecasting is weak. Second, donor-funded antidepressants arrive irregularly, creating gaps. Third, centralized distribution favors urban facilities, leaving rural clinics reliant on expired stock. The result is a system where patients are routinely exposed to the risks of abrupt discontinuation, even when they adhere to appointments.

Why Kenya's Mental Health Supply Chain Stalls

KEMSA is the primary procurer and distributor of essential medicines in Kenya. Its mandate includes antidepressants, but mental health receives less than 1% of the national health budget. A 2024 report by the Kenya Health Federation found that KEMSA's procurement of antidepressants covers only about 60% of estimated need. The remaining 40% is left to irregular donations from international partners, which often arrive with short expiration dates.

Donor-funded antidepressants, such as those from the Global Fund or USAID, are typically tied to specific programs — HIV or tuberculosis — and may not be distributed to general mental health clinics. When they are, the quantities are unpredictable. "We get a pallet of fluoxetine in January, then nothing for six months," says a pharmacist at a public clinic in Machakos who spoke on condition of anonymity. "We have to ration it. Patients who are stable get priority; new patients get whatever we have."

Centralized distribution further exacerbates disparities. KEMSA warehouses in Nairobi and Mombasa stock the majority of antidepressants, but rural clinics in counties like Turkana or Mandera may receive shipments only once per quarter. A 2023 study by the Kenya Medical Research Institute (KEMRI) found that rural facilities experienced stockouts of first-line antidepressants for an average of 12 weeks per year — three full months without consistent supply. During those gaps, clinicians prescribe from whatever stock remains, often older tricyclics with more side effects.

Budget allocation is a root cause. Kenya's mental health spending is estimated at 0.5% of the total health budget, far below the World Health Organization's recommendation of 5%. Of that, a tiny fraction goes to medicines. Most funds are consumed by staffing and infrastructure at the two national mental health hospitals — Mathare and Moi Teaching and Referral Hospital. Community clinics, where most patients seek care, are left with scant pharmacy budgets. "We can't order what we need because the county allocation is too small," says a county health officer in Kisumu. "We make do with what KEMSA sends."

The Evidence Gap: No Data on Regimen Cycling Outcomes

Kenya's Ministry of Health tracks aggregate consumption of antidepressants at the national level — total tablets dispensed per quarter — but does not record how many patients are forced to switch regimens. There is no national registry of medication changes due to stockouts. KEMSA reports show quantities ordered and delivered, but not whether those quantities match patient needs. The result is a blind spot: policymakers cannot measure the harm caused by supply disruptions.

The WHO's Model List of Essential Medicines includes six antidepressants for depression: amitriptyline, fluoxetine, imipramine, nortriptyline, sertraline, and escitalopram. But availability in Kenya varies by quarter. A 2024 audit by the Kenya Mental Health Alliance found that only fluoxetine and amitriptyline were consistently stocked in public facilities. Escitalopram and sertraline were available in fewer than half of surveyed clinics. This means patients like Grace are cycled between two or three drugs, even when guidelines recommend a broader choice for individual response.

Without patient-level data, clinicians rely on anecdote. Dr. Kamau estimates that roughly 30% of his patients have experienced at least one forced switch. "We need a system that tracks each patient's medication history across facilities. Without it, we can't know the true impact of stockouts on outcomes." The Ministry of Health has piloted an electronic medical records system in some counties, but it does not yet include mental health indicators. A 2025 evaluation by the Kenya Health Informatics Association found that fewer than 10% of mental health facilities use digital records for medication tracking.

The evidence gap extends to research. A systematic review published in the Journal of Global Health (2022) found only three studies from sub-Saharan Africa examining antidepressant supply continuity. None were from Kenya. The authors called for "urgent operational research" to quantify the burden of regimen cycling. Until then, the scale of the problem remains invisible to planners.

Clinicians Resort to Prescribing What Is Available

In Machakos County, doctors describe a practice they call "lottery medicine" — prescribing whatever antidepressant happens to be in stock. "We follow guidelines when we can, but often we can't," says Dr. Susan Mwangi, a medical officer at Machakos Level 5 Hospital. "If fluoxetine is out, we write for amitriptyline. If that's out, we try imipramine. The patient gets whatever is on the shelf." The result is a treatment plan determined not by clinical need but by supply chain logistics.

When public clinics run out entirely, clinicians may order non-formulary drugs from private pharmacies. Patients then pay out-of-pocket for a consistent supply. For Grace, that meant buying escitalopram from a private chemist at roughly 1,200 Kenyan shillings (about US$9) per month — a significant burden for a household living on less than US$100 per month. "I paid for three months, then I couldn't afford it anymore. The clinic gave me imipramine again."

Clinical guidelines from the Kenya Ministry of Health recommend that patients remain on the same antidepressant for 6–12 months after achieving remission. But when drugs change each visit, adherence drops. A 2023 study at Mathare Hospital found that adherence to antidepressant therapy fell below 40% among patients who experienced two or more medication switches within a year, compared to 70% among those on a stable regimen. "Patients lose confidence," says Dr. Kamau. "They think the medicine isn't working, so they stop taking it. Then the depression returns, and they blame themselves."

The consequences are measurable. Relapse rates after forced switches are high, and each relapse may require a longer treatment course. A 2021 analysis in the British Journal of Psychiatry estimated that preventing a single relapse could save health systems roughly US$500 in direct costs — a sum that dwarfs the cost of maintaining a steady drug supply. Yet Kenya's supply chain prioritizes procurement efficiency over continuity of care.

How Fixed-Dose Combinations and Buffer Stocks Could Help

Uganda offers a model. Uganda's National Medical Stores maintains a three-month buffer stock of essential antidepressants at district-level stores. When a clinic's supply runs low, it draws from the buffer, preventing stockouts. A 2023 evaluation by the Uganda Ministry of Health found that buffer stocks reduced antidepressant stockouts by 60% in pilot districts. The buffer system costs roughly 5% more per year in storage and inventory management, but it prevents the far greater costs of treatment failure.

Another approach is the use of fixed-dose combinations (FDCs) — single tablets containing two antidepressants. FDCs reduce the number of stock-keeping units (SKUs) that a pharmacy must manage. For example, a combination of fluoxetine and olanzapine (approved for treatment-resistant depression) could simplify procurement. But FDCs are not yet widely used in Kenya for mental health, partly because the WHO's Essential Medicines List includes only single-drug formulations for antidepressants.

WHO prequalification of generic antidepressants could also help. Currently, many antidepressants used in Kenya are sourced from Indian manufacturers that lack WHO prequalification, leading to quality concerns and supply delays. Prequalified products are more likely to have consistent supply chains. Kenya's pilot for an integrated supply chain, announced in early 2025, aims to centralize procurement of mental health medicines and link them to a real-time stock monitoring system. If successful, the pilot could reduce stockouts by improving demand forecasting.

Forecasting demand using prescription data is possible but requires digitization. Kenya's Health Information System (DHIS2) tracks outpatient visits and diagnoses, but not individual prescriptions. Linking prescription data to supply orders would allow KEMSA to predict which antidepressants are needed and in what quantities. A 2024 feasibility study by the University of Nairobi found that machine learning models using historical prescription data could reduce stockouts by up to 40%. But implementation would require investment in pharmacy training and data infrastructure.

Challenges to Implementing Buffer Stocks and Fixed-Dose Combinations

While buffer stocks and FDCs offer promise, they are not without obstacles. Buffer stocks require additional warehousing space and inventory management capacity, which are lacking in many rural Kenyan counties. The Uganda model succeeded partly because Uganda's National Medical Stores already had a robust distribution network; Kenya's KEMSA faces frequent transport delays and fuel shortages that could undermine buffer effectiveness. Moreover, buffer stocks tie up capital in unused inventory, which may be politically difficult to justify when budgets are tight. A county health officer in Kisumu notes: "We can't afford to have medicines sitting on shelves when we have shortages elsewhere. The buffer might help, but it needs upfront investment."

Fixed-dose combinations also face regulatory and clinical hurdles. The WHO Essential Medicines List currently includes only single-drug formulations for antidepressants, meaning FDCs would require separate approval by Kenya's Pharmacy and Poisons Board. Clinicians may be hesitant to prescribe FDCs because they reduce flexibility in dosing — a patient might need a different dose of one component than the other. Dr. Kamau cautions: "FDCs work for some conditions like HIV, but depression is more individual. We need to be able to adjust doses separately." Additionally, FDCs may not be cost-effective if they are more expensive than the sum of their components. A 2024 analysis by the Kenya Medical Research Institute estimated that FDCs for depression would cost roughly 15–20% more per course than separate tablets, though this could be offset by reduced stockout-related costs.

Another challenge is the risk of over-reliance on single suppliers. If Kenya centralizes procurement of antidepressants through KEMSA, a disruption at the supplier — such as a factory shutdown in India — could affect the entire system. Diversifying suppliers and maintaining multiple prequalified sources would mitigate this risk, but it requires additional regulatory oversight. Despite these challenges, many experts argue that the status quo of frequent stockouts is costlier in human and economic terms. The Ugandan buffer stock model, despite its upfront costs, has proven sustainable over three years, and Kenya could adapt it with phased implementation starting in high-burden counties.

Patients' Trust Erodes When Treatment Keeps Changing

Grace Anyango now doubts whether any antidepressant works for her. "I've tried five. Maybe I'm the problem," she says quietly. Her trust in the health system has eroded. She missed her last two appointments at Mathare because she felt it was pointless. "They'll just give me another drug, and I'll start all over again." Stigma compounds the issue. In Kibera, mental illness is often seen as a personal failing. When symptoms persist despite treatment, neighbors and family members may blame the patient for not "trying hard enough."

Self-medication with herbal remedies is rising. A 2025 survey by the Kenya Mental Health Alliance found that 30% of patients who experienced antidepressant stockouts had tried herbal alternatives, such as St. John's wort or local concoctions. These remedies may interact with antidepressants or cause side effects, further complicating care. Community health workers report that patients often stop taking prescribed medications when they start herbal treatments, leading to withdrawal symptoms and relapse.

Community health workers like Mary Wanjiku try to keep patients engaged. "I visit them at home. I explain that the medicine changes are not their fault. But it's hard when the system keeps failing." She estimates that attendance at her local clinic dropped by 25% in the past year, coinciding with repeated stockouts. "Patients say, 'Why go if they don't have the medicine?'"

Restoring supply continuity is cheaper than managing relapse. A 2024 cost analysis by the Kenya Health Economics Association estimated that each patient who relapses due to a forced switch incurs an average of US$150 in additional treatment costs — clinic visits, new prescriptions, and lost productivity. Ensuring a steady supply of antidepressants for that same patient would cost roughly US$30 per year. Yet the system continues to underinvest in supply chain resilience. For Grace, the cost is not just financial. "I want to feel better," she says. "I want to be there for my children. But I don't know if I will ever get the right medicine."

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individuals experiencing depression should consult a qualified healthcare provider for personalized treatment recommendations.